美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Militia Long/Short Equity ETF

28.80

-0.2938-1.01%

成交量：1.88万

成交额：54.28万

市值：- -

市盈率：- -

高：28.94

开：28.81

低：28.76

收：29.09

数据加载中...

总览公司新闻公告

概念

no data

没有相关数据

资金流向

资金流入：

资金流出：

新闻

4882万元收购一家公司，买断CLDN18.2核心双抗权利

动脉新医药

巨头加码，三抗成为“新风口”

医药生物行业周报：艾伯维引进CD3／BCMA／CD38三抗关注国内三抗布局创新药企

甬兴证券有限公司

上半年20起大型药企与中国创新药公司交易！

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/ORR"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":28.7957,"timestamp":1752868800000,"preClose":29.0895,"halted":0,"volume":18822,"delay":0,"floatShares":3200000,"shares":0,"eps":0,"marketStatus":"盘后交易","change":-0.2938,"latestTime":"07-18 18:53:42 EDT","open":28.81,"high":28.94,"low":28.76,"amount":542792.1999,"amplitude":0.006188,"askPrice":43.2,"askSize":200,"bidPrice":28.78,"bidSize":500,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1752883200000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":29.0895,"sharesOutstanding":3200000,"nav":28.83,"aum":92256000,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":28.75,"preClose":29.0895,"latestTime":"09:09 EDT","volume":31,"amount":891.25,"timestamp":1752844179206},"volumeRatio":0.38178},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":3200000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.38178,"shares":0,"dividePrice":0,"high":28.94,"amplitude":0.006188,"preClose":29.0895,"low":28.76,"week52Low":25.63,"pbRate":"--","week52High":30.215,"institutionHeld":0,"latestPrice":28.7957,"committee":0.428571,"eps":0,"divideRate":0,"volume":18822,"delay":0,"ttmEps":0,"open":28.81,"prevYearClose":25.88,"prevWeekClose":28.9706,"prevMonthClose":29.28,"prevQuarterClose":29.28,"fiveDayClose":28.9706,"twentyDayClose":28.6963,"sixtyDayClose":28.2935},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ORR\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2552469590","title":"4882万元收购一家公司，买断CLDN18.2核心双抗权利","url":"https://stock-news.laohu8.com/highlight/detail?id=2552469590","media":"动脉新医药","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552469590?lang=zh_cn&edition=fundamental","pubTime":"2025-07-18 17:51","pubTimestamp":1752832275,"startTime":"0","endTime":"0","summary":"当前，胃癌CLDN18.2靶点的竞争激烈，除了已上市的zolbetuximab，还有多款ADC产品在研发中。然而，Zolbetuximab主要针对CLDN18.2高表达患者，且在治疗过程中可能引发一些安全性问题，如恶心、呕吐等不良反应。据介绍，此次收购的Bridge Health，持有givastomig需使用的CLDN18.2亲本抗体。这些特性对givastomig成为治疗Claudin 18.2阳性癌症潜在同类最佳双特异性抗体有着核心差异化优势。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718175353a6b1e0e3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718175353a6b1e0e3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4505","BK4526","ORR","BK4535","IMAB"],"gpt_icon":0},{"id":"2552107687","title":"巨头加码，三抗成为“新风口”","url":"https://stock-news.laohu8.com/highlight/detail?id=2552107687","media":"药智网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552107687?lang=zh_cn&edition=fundamental","pubTime":"2025-07-17 16:03","pubTimestamp":1752739384,"startTime":"0","endTime":"0","summary":"ISB 2001在组合中加入CD38，增强对BCMA低表达肿瘤细胞的结合能力，并通过下调抗原表达来阻止癌症产生耐药性，有望成为新一代治疗多发性骨髓瘤的药物。02三抗正在成为新风口单克隆抗体药物因其特异性强、靶向性高和毒副作用小等特点，已在肿瘤、自身性免疫疾病等领域广泛应用。目前，全球已有多款双特异性抗体药物获批上市，适应证主要集中在肿瘤领域。在国内药企中，三特异性抗体同样受到追崇。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717161118a6af3e8d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717161118a6af3e8d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2065731478.USD","IE0031619046.USD","ORR","JNJ","BK4077","CR","BK4006","IE00B66KJ199.SGD","MRK","IE00B19Z4B17.USD","BK4161","PFE","IE00B7SZL793.SGD","CRS","AZN","SLE","IGI"],"gpt_icon":0},{"id":"2552177419","title":"医药生物行业周报：艾伯维引进CD3／BCMA／CD38三抗 关注国内三抗布局创新药企","url":"https://stock-news.laohu8.com/highlight/detail?id=2552177419","media":"甬兴证券有限公司","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2552177419?lang=zh_cn&edition=fundamental","pubTime":"2025-07-17 00:00","pubTimestamp":1752681600,"startTime":"0","endTime":"0","summary":"恒生医疗保健指数上涨0.05%，板块整体跑输恒生指数0.88pct。在恒生12 个一级子行业中，医疗保健行业周涨跌幅排名为第9 位。核心观点重磅交易落地，艾伯维引进CD3/BCMA/CD38 管线。投 资建议此次艾伯维引进CD3/BCMA/CD38三抗，进一步点燃了三抗赛道的热情，建议关注国内有三抗布局的企业，如泽璟制药-U、信达生物、神州细胞、基石药业-B、先声药业、汇宇制药-W、恒瑞医药等。风险提示销售不及预期风险，医药政策影响不确定的风险，新药研发失败风险。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071709103597a911ec&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071709103597a911ec&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE0002270589.USD","IE00BGHQF631.EUR","LU0234570918.USD","LU1861214812.USD","BK4566","LU0648001328.SGD","LU2129689514.USD","LU0345781412.USD","LU0211327993.USD","BK4585","LU0985320562.USD","LU1934455277.USD","LU0320765646.SGD","LU1917777945.USD","LU1064131342.USD","LU0689472784.USD","LU1861219969.SGD","SG9999004303.SGD","LU2264538146.SGD","LU0965508806.USD","SG9999011175.SGD","LU1003077747.HKD","LU0942090050.USD","SG9999001440.SGD","LU2129689431.USD","ABBV","SG9999015986.USD","IE00B4R5TH58.HKD","SGXZ23171101.USD","LU0122379950.USD","LU0868494617.USD","LU0417517546.SGD","LU1988902786.USD","LU1732800096.USD","IE0004445239.USD","BK4152","LU1291159041.SGD","IE00BKVL7J92.USD","BK4588","LU2237443895.HKD","LU1496350502.SGD","LU0310800379.SGD","DE","LU0965509010.AUD","LU1093756168.USD","LU1720051108.HKD","LU2112291526.USD","LU2023251221.USD","ORR","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"2551141731","title":"上半年20起大型药企与中国创新药公司交易！","url":"https://stock-news.laohu8.com/highlight/detail?id=2551141731","media":"创鉴汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551141731?lang=zh_cn&edition=fundamental","pubTime":"2025-07-16 17:08","pubTimestamp":1752656931,"startTime":"0","endTime":"0","summary":"2025年上半年，大型药企与中国创新药公司之间的交易活动活跃度提高，反映出中国在全球创新药领域的快速崛起和强大吸引力。根据创鉴汇不完全统计，上半年中国创新药企与大型药企共达成20笔交易，披露的交易潜在总金额近300亿美元，其中单笔最高达60.5亿美元，显示出大型药企对中国创新药的高度信心。协议包括首付款8000万美元，潜在交易总额20.1亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716174021a44e69e4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716174021a44e69e4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2417539215.USD","MSD","BK4080","LU2236285917.USD","SG9999002232.USD","01530","01093","BK4007","BK4599","LU0868494617.USD","LU0889565916.HKD","LU0225284248.USD","SG9999001176.SGD","BK4581","ORR","03692","BK4588","IE00B19Z3B42.SGD","AZN","SGXZ57979304.SGD","LU1066051498.USD","BK4592","SG9999003800.SGD","SG9999001176.USD","LU2462157665.USD","BK4534","LU0306806265.USD","LU2456880835.USD","MRK","BK4550","LU0234572021.USD","LU1894683348.USD","LU0321505868.SGD","IE000M9KFDE8.USD","LU0321505439.SGD","LU1883839398.USD","BK4585","LU0170899867.USD","LU0456855351.SGD","LU1894683264.USD","SG9999011175.SGD","IE00BBT3K403.USD","IE00B19Z3581.USD","IE00BLSP4239.USD","IE00BLSP4452.SGD","LU0109394709.USD","LU0122379950.USD","PFE","LU0985481810.HKD","IE0002270589.USD","LU0306807586.USD","ADC","SG9999002224.SGD"],"gpt_icon":0}],"pageSize":4,"totalPage":7,"pageCount":1,"totalSize":28,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{}}}